Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1132-1141

  Chi, Alexander ^a   Liao, Zhongxing ^b   Nguyen, Nam P ^a   Howe, Carol ^c   Gomez, Daniel ^b   Jang, Si Young ^a   Komaki, Ritsuko ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Extrapleural pneumonectomy; IMRT; Malignant pleural mesothelioma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; METHOTREXATE; NAVELBINE; PEMETREXED; RALTITREXED; VINBLASTINE;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER SURVIVAL; ESOPHAGITIS; ESOPHAGUS FISTULA; EXTRAPLEURAL PNEUMONECTOMY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG RESECTION; LUNG TOXICITY; MALIGNANT MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PATIENT MONITORING; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; REVIEW; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 79958175112     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182199819     Document Type: Article

References (62)

1. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.
2. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576-588.
3. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;46:2736-2740. (Pubitemid 11210245)
4. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108-115. (Pubitemid 43939037)
5. Takagi A, Hirose A, Nishimura T, et al. Induction of mesothelioma in p53+/ - mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008;33:105-116. (Pubitemid 351340768)
6. McLaren BR, Haenel T, Stevenson S, et al. Simian virus (SV) 40 like sequences in cell lines and tumor biopsies from Australian malignant mesotheliomas. Aust N Z J Med 2000;30:450-456.
7. Gulmez I, Kart L, Buyukoglan H, et al. Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J 2004;11:287-290. (Pubitemid 39089580)
8. Jänne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin 2004;14:567-573. (Pubitemid 39314491)
9. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 1997;4:215-222. (Pubitemid 127725247)
10. Stevens CW, Forster KM, Smythe WR, et al. Radiotherapy for mesothelioma. Hematol Oncol Clin North Am 2005;19:1099-1115. (Pubitemid 41736045)
11. Gupta V Mychalczak B Krug L et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005;63:1045-1052. (Pubitemid 41505282)
12. Lee TT, Everett DL, Shu H-KG, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002;124:1183-1189. (Pubitemid 35417006)
13. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122: 788-795.
14. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334-338. (Pubitemid 27084548)
15. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
16. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-1202. (Pubitemid 47244366)
17. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumo-nectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996;224:288-294.
18. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007;57:89-95. (Pubitemid 46843340)
19. Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in western Australia. J Thorac Oncol 2009;4:1010-1016.
20. Batirel HF, Metintas M, Caglar HB, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 2008;3:499-504. (Pubitemid 351630277)
21. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneu-monectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
22. de Perrot M, Feld R, Cho J, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-1418.
23. Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-1369.
24. Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 2009;88:870-876.
25. Okubo K, Sonobe M, Fujinaga T, et al. Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg 2009;57:585-590.
26. Pagan V, Ceron L, Paccagnella A, et al. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. J Cardiovasc Surg 2006;47:595-601. (Pubitemid 44696791)
27. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006;1:289-295. (Pubitemid 47163979)
28. Maggi G, Casadio C, Cianci R, et al. Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2001;19: 346-350. (Pubitemid 32197443)
29. Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys 2007;68:1366-1374. (Pubitemid 47176807)
30. Forster KM, Smythe WR, Starkschall G, et al. Intensity-modulated radiotherapy follow extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys 2003;55:606-616. (Pubitemid 36170001)
31. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-1693. (Pubitemid 47588107)
32. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesotheliom. Int J Radiat Oncol Biol Phys 2006;65:640-645. (Pubitemid 43795851)
33. Gupta V, Krug LM, Laser B, et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol 2009;4:746-750.
34. van Sandick JW, Kappers I, Baas P, et al. Surgical treatment in the management of malignant pleural mesothelioma: a single institution's experience. Ann Surg Oncol 2008;15:1757-1764.
35. Miles EF, Larrier NA, Kelsey CR, et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 2008;71:1143-1150.
36. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007;69:350-357. (Pubitemid 47381562)
37. Kristensen CA, Nøttrup TJ, Berthelsen AK, et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 2009;92:96-99.
38. Du KL, Both S, Friedberg JS, et al. Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2010; 10:425-429.
39. Allen AM, Schofield D, Hacker F, et al. Restricted field IMRT dramatically enhances IMRT planning for mesothelioma. Int J Radiat Oncol Biol Phys 2007;69:1587-1592. (Pubitemid 350116418)
40. Stevens CW, Wong P, Rice D, et al. Treatment planning system evaluation for mesothelioma IMRT. Lung Cancer 2005;49(Suppl 1):75-81.
41. Zhu XR, Prado K, Liu HH, Guerrero TM, et al. Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency. Int J Radiat Oncol Biol Phys 2005;62:1525-1534. (Pubitemid 40982079)
42. Jang SY, Liu HH, Wang X, et al. Underestimation of low-dose radiation in treatment planning of intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;71:1537-1546.
43. Court LE, Ching D, Schofield D, et al. Evaluation of the dose calculation accuracy in intensity-modulated radiation therapy for mesothelioma, focusing on low doses to the contralateral lung. J Appl Clin Med Phys 2009;10:34-42.
44. Fenwick JD, Tomé WA, Soisson ET, et al. Tomotherapy and other innovative IMRT delivery systems. Semin Radiat Oncol 2006;16:199-208. (Pubitemid 44436960)
45. Chen AM, Lee NY, Yang CC, et al. Comparison of intensity-modulated radiotherapy using helical tomotherapy and segmental multileaf collimator-based techniques for nasopharyngeal carcinoma: dosimetric analysis incorporating quality assurance guidelines from RTOG 0225. Technol Cancer Res Treat 2010;9:291-298.
46. Chen YJ, Liu A, Han C, et al. Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim 2007;32:166-171. (Pubitemid 47239417)
47. Sterzing F, Sroka-Perez G, Schubert K, et al. Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step-and-shoot IMRT. Radiother Oncol 2008;86:251-257.
48. Scorsetti M, Bignardi M, Clivio A, et al. Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study. Int J Radiat Oncol Biol Phys 2010;77:942-949.
49. Krayenbuehl J, Hartmann M, Lomax AJ, et al. Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. Int J Radiat Oncol Biol Phys 2010;78:628-634.
50. Suit H, Urie M. Proton beams in radiation therapy. J Natl Cancer Inst 1992;84:155-164.
51. Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest 2004;125:489-493. (Pubitemid 38223628)
52. Ceresoli GL, Chiti A, Zucali PA, et al. Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev 2007;33:533-541. (Pubitemid 47355343)
53. Nowak AK, Armato SG III, Ceresoli GL, et al. Imaging in pleural mesothelioma: a review of imaging research presented at the 9th international meeting of the international mesothelioma interest group. Lung Cancer 2010;70:1-6.
54. 18F] fluorodeoxyglucose. J Clin Oncol 2006;24:4587-4593. (Pubitemid 46630956)
55. Tan C, Barrington S, Rankin S, et al. Role of integrated 18-fluorode-oxyglucose positron emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol 2010;5:385-388.
56. Cao CQ, Yan TD, Bannon PG, et al. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010;5:1692-1703.
57. Ahamad A, Stevens CW, Smythe WR, et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003;55:768-775. (Pubitemid 36170016)
58. Komaki R, Liao Z, Liu H, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to Allen et al. (Int J Radiat Oncol Biol Phys 2006;65:640-645).
59. Int J Radiat Oncol Biol Phys 2006;66:1595-1596; author reply 1596.
60. Hill-Kayser CE, Avery S, Mesina CF, et al. Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques. J Thorac Oncol 2009;4:1431-1437.
61. Krayenbuehl J, Oertel S, Davis JB, et al. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys 2007;69:1593-1599. (Pubitemid 350116423)
62. Chan MF, Chui CS, Song Y, et al. A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons. Radiother Oncol 2006;79:218-223. (Pubitemid 43884944)